S&P 500   3,912.16 (+2.65%)
DOW   31,643.94 (+2.30%)
QQQ   323.39 (+2.94%)
AAPL   127.38 (+5.05%)
MSFT   236.96 (+1.97%)
FB   265.72 (+3.14%)
GOOGL   2,070.55 (+2.41%)
TSLA   712.26 (+5.44%)
AMZN   3,136.25 (+1.40%)
NVDA   549.42 (+0.15%)
BABA   242.03 (+1.80%)
CGC   34.61 (+5.68%)
GE   13.23 (+5.50%)
MU   94.55 (+3.30%)
NIO   50.08 (+9.39%)
AMD   86.18 (+1.98%)
T   28.27 (+1.36%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.72 (+3.53%)
BA   224.72 (+6.00%)
NFLX   549.19 (+1.92%)
BAC   35.99 (+3.69%)
S&P 500   3,912.16 (+2.65%)
DOW   31,643.94 (+2.30%)
QQQ   323.39 (+2.94%)
AAPL   127.38 (+5.05%)
MSFT   236.96 (+1.97%)
FB   265.72 (+3.14%)
GOOGL   2,070.55 (+2.41%)
TSLA   712.26 (+5.44%)
AMZN   3,136.25 (+1.40%)
NVDA   549.42 (+0.15%)
BABA   242.03 (+1.80%)
CGC   34.61 (+5.68%)
GE   13.23 (+5.50%)
MU   94.55 (+3.30%)
NIO   50.08 (+9.39%)
AMD   86.18 (+1.98%)
T   28.27 (+1.36%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.72 (+3.53%)
BA   224.72 (+6.00%)
NFLX   549.19 (+1.92%)
BAC   35.99 (+3.69%)
S&P 500   3,912.16 (+2.65%)
DOW   31,643.94 (+2.30%)
QQQ   323.39 (+2.94%)
AAPL   127.38 (+5.05%)
MSFT   236.96 (+1.97%)
FB   265.72 (+3.14%)
GOOGL   2,070.55 (+2.41%)
TSLA   712.26 (+5.44%)
AMZN   3,136.25 (+1.40%)
NVDA   549.42 (+0.15%)
BABA   242.03 (+1.80%)
CGC   34.61 (+5.68%)
GE   13.23 (+5.50%)
MU   94.55 (+3.30%)
NIO   50.08 (+9.39%)
AMD   86.18 (+1.98%)
T   28.27 (+1.36%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.72 (+3.53%)
BA   224.72 (+6.00%)
NFLX   549.19 (+1.92%)
BAC   35.99 (+3.69%)
S&P 500   3,912.16 (+2.65%)
DOW   31,643.94 (+2.30%)
QQQ   323.39 (+2.94%)
AAPL   127.38 (+5.05%)
MSFT   236.96 (+1.97%)
FB   265.72 (+3.14%)
GOOGL   2,070.55 (+2.41%)
TSLA   712.26 (+5.44%)
AMZN   3,136.25 (+1.40%)
NVDA   549.42 (+0.15%)
BABA   242.03 (+1.80%)
CGC   34.61 (+5.68%)
GE   13.23 (+5.50%)
MU   94.55 (+3.30%)
NIO   50.08 (+9.39%)
AMD   86.18 (+1.98%)
T   28.27 (+1.36%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.72 (+3.53%)
BA   224.72 (+6.00%)
NFLX   549.19 (+1.92%)
BAC   35.99 (+3.69%)
Log in
TSE:CMED

(CMED.TO) Stock Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume52,208 shs
Average Volume387,394 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CanniMed Therapeutics Inc. operates as a plant biopharmaceutical company that specializes in medical cannabis. The company cultivates and sells pharmaceutical-grade cannabis products in dried herbal and oil forms for Canadian patients. It also offers herbal cannabis and cannabis oil; and vaporizers, consumable vaporizer accessories, and herb mills. In addition, the company offers a plant biotechnology research and product development program that focuses on the production of plant-based materials for pharmaceutical, agricultural, and environmental applications. CanniMed Therapeutics Inc. was founded in 1988 and is based in Saskatoon, Canada. As of March 28, 2018, CanniMed Therapeutics Inc. operates as a subsidiary of Aurora Cannabis Inc.

Headlines

Why Aurora Cannabis Is Trading Higher Today - Benzinga
September 22, 2020 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry N/A
Sub-IndustryCannabis
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-306-9751207
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.62 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive CMED News and Ratings via Email

Sign-up to receive the latest news and ratings for CMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











(CMED.TO) (TSE:CMED) Frequently Asked Questions

What stocks does MarketBeat like better than (CMED.TO)?

Wall Street analysts have given (CMED.TO) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (CMED.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are (CMED.TO)'s key executives?

(CMED.TO)'s management team includes the following people:
  • Mr. Andre Jerome, CEO & Director
  • Mr. John Lewis Knowles BComm., CPA, C.A., CFO, Corp. Sec. & Non-Independent Director (Age 63)
  • Mr. Howard Harkness, VP of Marketing & Sales

Who are some of (CMED.TO)'s key competitors?

What other stocks do shareholders of (CMED.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (CMED.TO) investors own include Aurora Cannabis Inc. (ACB.TO) (ACB), Canopy Growth (WEED), Smith & Nephew (SNN), (THCX.V) (THCX), CannTrust (CTST), Cronos Group (CRON), (MJN.V) (MJN), CannaRoyalty (CNNRF), KushCo (KSHB) and Leaf Mobile (LEAF).

What is (CMED.TO)'s stock symbol?

(CMED.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CMED."

How do I buy shares of (CMED.TO)?

Shares of CMED and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does (CMED.TO) make?

(CMED.TO) has a market capitalization of C$0.00.

What is (CMED.TO)'s official website?

The official website for (CMED.TO) is www.cannimedtherapeutics.com.

Where are (CMED.TO)'s headquarters?

(CMED.TO) is headquartered at 1 Plant Technology Road, Box 19A, RR #5, SASKATOON, SK S7K 3J8, Canada.

How can I contact (CMED.TO)?

(CMED.TO)'s mailing address is 1 Plant Technology Road, Box 19A, RR #5, SASKATOON, SK S7K 3J8, Canada. The company can be reached via phone at +1-306-9751207.


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.